Dyne Therapeutics (US.DYN)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.DYN · YoY: 2026 H1 vs 2025 H1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.6% | → |
| ROE | -42.6% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.31 | ↓ |
| Gross Margin | - | → |
US.DYN (Dyne Therapeutics) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.6% → ROE -42.6% ↓ Cash Conversion - → D/E Ratio 0.31 ↓ Gross Margin - →
Key Metrics
US.DYN (Dyne Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.6% →ROE -42.6% ↓Cash Conversion - →D/E Ratio 0.31 ↓Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies